Press Releases

Press Releases

or

October 1, 2018
BeiGene Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) CAMBRIDGE, Mass. and BEIJING, China, Oct. 01, 2018 (GLOBE NEWSWIRE) --  BeiGene, Ltd.  (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly
September 25, 2018
BeiGene to Present at Upcoming Investor Conferences CAMBRIDGE, Mass. and BEIJING, China, Sept. 25, 2018 (GLOBE NEWSWIRE) --  BeiGene, Ltd.  (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and
September 21, 2018
BeiGene Announces Preliminary Results from the Phase 1 Clinical Trial of Zanubrutinib in Chinese Patients with B-Cell Lymphoma at Annual Meeting of the Chinese Society of Clinical Oncology BEIJING, China and CAMBRIDGE, Mass., Sept. 21, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX:
September 20, 2018
BeiGene Presents Preliminary Results on Anti-PD-1 Antibody Tislelizumab in Patients with Microsatellite Instability-High or Mismatch Repair-Deficient Solid Tumors at Annual Meeting of the Chinese Society of Clinical Oncology BEIJING, China and CAMBRIDGE, Mass., Sept.
September 4, 2018
BeiGene Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) CAMBRIDGE, Mass., and BEIJING, China, Sept. 04, 2018 (GLOBE NEWSWIRE) --  BeiGene, Ltd.  (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative